Mirati Therapeutics, Inc.
MRTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | -4.49 | 0.21 | -0.24 |
| FCF Yield | -5.08% | -6.28% | -8.83% | -4.96% |
| EV / EBITDA | -15.34 | -10.88 | -10.16 | -11.52 |
| Quality | ||||
| ROIC | -17.08% | -23.92% | -20.08% | -20.17% |
| Gross Margin | 84.49% | 90.63% | 88.60% | -15,085.87% |
| Cash Conversion Ratio | 0.89 | 0.74 | 1.03 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.61% | 27.51% | 12.90% | -2.45% |
| Free Cash Flow Growth | -8.80% | 30.63% | -46.94% | 6.79% |
| Safety | ||||
| Net Debt / EBITDA | 1.22 | 0.43 | 1.03 | 0.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.15 | 0.21 | 46.97 |
| Cash Conversion Cycle | -839.42 | -1,570.74 | -1,956.55 | 60.61 |